{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:41:21Z","timestamp":1780609281154,"version":"3.54.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Besides being an essential structural component of plasma membranes and the precursor of many functional compounds and signaling molecules, cholesterol was also proposed to play a role in the etiology and\/or manifestation of Parkinson\u2019s disease (PD). However, so far systematic investigations on the role of cholesterol and its metabolites present in the brain for the etiology of PD are missing. Here, we investigate for the first time the association of PD with SNPs in the genes of four cytochromes P450 (P450), CYP46A1, CYP39A1, CYP27A1 and CYP7B1, which are critical for the degradation of cholesterol in the brain. Analyzing 1,349 individuals from the PPMI data base, we found 24 SNPs in these four genes, which are significantly over- or under-represented in patients suffering from idiopathic PD (IPD). Studying each of the 362 IPD patients individually, we found that most patients (45%) showed only one associated SNP in one of the four P450 genes, while 31% displayed two associated SNPs and 18% three associated SNPs. The occurrence of some associated SNPs is in the same order of magnitude as SNPs in the GBA (beta-glucocerebrosidase) and thus might reflect a genetic predisposition for PD. As all 24 SNPs were located in introns and 3\u2032 untranslated regions, we evaluated the prospective regulatory impact of the surrounding genomic regions by using transcriptome and epigenome data from the Foundational Data Initiative for Parkinson Disease (FOUNDIN-PD). FOUNDIN-PD provides gene expression, open chromatin and DNA methylation data in a cohort of 89 induced pluripotent stem cell (iPSC) lines differentiated to dopaminergic (DA) neurons derived from people in the PPMI study. Indeed, two of the 24 SNPs, one in CYP7B1 (rs118111353) and the other one in CYP27A1 (rs74446825), were localized within a region of open chromatin in differentiated neurons. Interestingly, all iPSC lines with open chromatin in rs118111353 showed the reference allele. As all four P450, CYP46A1, CYP39A1, CYP27A1 and CYP7B1, are expressed in dopaminergic neurons, we discuss further functional studies to connect SNPs in regulatory regions with gene expression levels. Finally, potential possibilities for personalized therapeutic treatment of patients with SNPs in the four investigated P450 are discussed.<\/jats:p>","DOI":"10.3389\/fphar.2024.1477009","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:44:06Z","timestamp":1727685846000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["SNPs in cytochromes P450 catalyzing cholesterol degradation in brain are associated with Parkinson\u2019s disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Polina","family":"Petkova-Kirova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kolchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Michael","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Maria","family":"Schulze-Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","article-title":"Role of brain liver X receptor in Parkinson's disease: Hidden Treasure and emerging Opportunities","volume":"61","author":"Alnaaim","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s11033-023-08459-5","article-title":"Orexin pathway in Parkinson's disease: a review","volume":"50","author":"Alrouji","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J. Neurochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"111237","DOI":"10.1016\/j.mce.2021.111237","article-title":"Underestimated reactions and regulation patterns of adrenal cytochromes P450","volume":"530","author":"Bernhardt","year":"2021","journal-title":"Mol. Cell Endocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00041433-199904000-00010","article-title":"Removal of cholesterol from extrahepatic sources by oxidative mechanisms","volume":"10","author":"Bjorkhem","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neulet.2013.09.003","article-title":"Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease","volume":"555","author":"Bjorkhem","year":"2013","journal-title":"Neurosci. Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bjorkhem","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3389\/fneur.2018.00756","article-title":"24S-Hydroxycholesterol correlates with Tau and is increased in cerebrospinal fluid in Parkinson's disease and Corticobasal Syndrome","volume":"9","author":"Bjorkhem","year":"2018","journal-title":"Front. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/JPD-230250","article-title":"The etiology of Parkinson's disease: new Perspectives from gene-Environment Interactions","volume":"13","author":"Bogers","year":"2023","journal-title":"J. Park. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nchembio782","article-title":"Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization","volume":"2","author":"Bosco","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.xgen.2023.100261","article-title":"The Foundational Data Initiative for Parkinson Disease: Enabling efficient translation from genetic maps to mechanism","volume":"3","author":"Bressan","year":"2023","journal-title":"Cell Genom"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/mds.29577","article-title":"27-Hydroxycholesterol Drives the Spread of \u03b1-synuclein pathology in Parkinson's disease","volume":"38","author":"Dai","year":"2023","journal-title":"Mov. Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J. Lipid Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S3-S8","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Park. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6715","DOI":"10.1523\/JNEUROSCI.1594-04.2004","article-title":"Lipid rafts mediate the synaptic localization of alpha-synuclein","volume":"24","author":"Fortin","year":"2004","journal-title":"J. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.chemrestox.6b00226","article-title":"Intersection of the roles of cytochrome P450 enzymes with xenobiotic and Endogenous substrates: relevance to Toxicity and drug Interactions","volume":"30","author":"Guengerich","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbagen.2006.07.017","article-title":"Cytochrome P450 systems--biological variations of electron transport chains","volume":"1770","author":"Hannemann","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1094265","DOI":"10.3389\/fphar.2022.1094265","article-title":"A CYPome-wide study reveals new potential players in the pathogenesis of Parkinson's disease","volume":"13","author":"Hartz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"108670","DOI":"10.1016\/j.isci.2023.108670","article-title":"Inhibition of 7\u03b1,26-dihydroxycholesterol biosynthesis promotes midbrain dopaminergic neuron development","volume":"27","author":"Hennegan","year":"2024","journal-title":"iScience"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","article-title":"Total cholesterol and the risk of Parkinson disease","volume":"70","author":"Hu","year":"2008","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.27609","article-title":"Brain cholesterol metabolism and Parkinson's disease","volume":"34","author":"Huang","year":"2019","journal-title":"Mov. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.5607\/en.2019.28.5.554","article-title":"Cholesterol metabolism in the brain and its association with Parkinson's disease","volume":"28","author":"Jin","year":"2019","journal-title":"Exp. Neurobiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116442","DOI":"10.1016\/j.biopha.2024.116442","article-title":"Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of \u03b1-synuclein propagation: Implications in Parkinson's disease","volume":"174","author":"Kim","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/metabo11010029","article-title":"Gut Microbiota Dysbiosis is associated with Elevated bile acids in Parkinson's disease","volume":"11","author":"Li","year":"2021","journal-title":"Metabolites"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","article-title":"cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain","volume":"96","author":"Lund","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1073\/pnas.93.18.9799","article-title":"Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation","volume":"93","author":"Lutjohann","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exger.2014.09.013","article-title":"Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?","volume":"68","author":"Marwarha","year":"2015","journal-title":"Exp. Gerontol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100555","DOI":"10.1016\/j.jlr.2024.100555","article-title":"Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz","volume":"65","author":"Mast","year":"2024","journal-title":"J. Lipid Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","article-title":"Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice","volume":"289","author":"Mast","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.bbalip.2010.03.005","article-title":"Marked variability in hepatic expression of cytochromes CYP7A1 and CYP27A1 as compared to cerebral CYP46A1. Lessons from a dietary study with omega 3 fatty acids in hamsters","volume":"1801","author":"Mast","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.3390\/ijms21093309","article-title":"Orphan nuclear receptor ROR\u03b1 regulates Enzymatic metabolism of cerebral 24S-hydroxycholesterol through CYP39A1 intronic response Element activation","volume":"21","author":"Matsuoka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/ane.13329","article-title":"Community-based genetic study of Parkinson's disease in Estonia","volume":"143","author":"Muldmaa","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1244516","DOI":"10.3389\/fphar.2023.1244516","article-title":"SNPs in cytochrome P450 genes decide on the fate of individuals with genetic predisposition to Parkinson's disease","volume":"14","author":"Petkova-Kirova","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.37349\/ent.2021.00013","article-title":"Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases","volume":"1","author":"Pikuleva","year":"2021","journal-title":"Explor Neuroprotective Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"696778","DOI":"10.3389\/fnagi.2021.696778","article-title":"Cholesterol hydroxylating cytochrome P450 46A1: from mechanisms of action to clinical Applications","volume":"13","author":"Pikuleva","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"136767","DOI":"10.1016\/j.neulet.2022.136767","article-title":"Glucocerebrosidase variant T369M is not a risk factor for Parkinson's disease in Sweden","volume":"784","author":"Ran","year":"2022","journal-title":"Neurosci. Lett."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1146\/annurev.biochem.78.072407.103859","article-title":"Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain","volume":"78","author":"Russell","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fneur.2020.00570","article-title":"Genomic analysis Identifies new loci associated with motor Complications in Parkinson's disease","volume":"11","author":"Ryu","year":"2020","journal-title":"Front. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/03602530701498455","article-title":"Inhibition of cytochromes p450: existing and new promising therapeutic targets","volume":"39","author":"Schuster","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1212\/WNL.0b013e3181b28601","article-title":"Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset","volume":"73","author":"Sidransky","year":"2009","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease Epidemiology, pathology, genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.1073\/pnas.1322807111","article-title":"Oxysterols are agonist ligands of ROR\u03b3t and drive Th17 cell differentiation","volume":"111","author":"Soroosh","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B46","doi-asserted-by":"publisher","first-page":"28485","DOI":"10.1074\/jbc.R109.042168","article-title":"CYP7B1: one cytochrome P450, two human genetic diseases, and multiple physiological functions","volume":"284","author":"Stiles","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"804261","DOI":"10.3389\/fnins.2022.804261","article-title":"Methylated cytochrome P450 and the Solute Carrier family of genes correlate with Perturbations in bile acid metabolism in Parkinson's disease","volume":"16","author":"Vishweswaraiah","year":"2022","journal-title":"Front. Neurosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1194\/jlr.M300164-JLR200","article-title":"Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration","volume":"44","author":"Xie","year":"2003","journal-title":"J. Lipid Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1021\/acschemneuro.3c00671","article-title":"Phospholipids and cholesterol Determine molecular mechanisms of Cytotoxicity of \u03b1-synuclein oligomers and fibrils","volume":"15","author":"Zhaliazka","year":"2024","journal-title":"ACS Chem. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:44:08Z","timestamp":1727685848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":49,"alternative-id":["10.3389\/fphar.2024.1477009"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1477009","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1477009"}}